Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey

  Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative
  Sites in New CenterWatch Survey

Business Wire

BOSTON -- March 4, 2013

More than 2,000 global investigative sites rate the best biopharmaceutical
companies to work for in a new survey conducted by CenterWatch, a leading
provider of global clinical trials information. The survey results were
released today in the March issue of The CenterWatch Monthly newsletter.

Biogen Idec, Forest Laboratories and Bayer claimed the top three spots in
CenterWatch’s bi-annual 2013 Global Investigative Site Relationship survey,
receiving the highest average rating across 36 relationship attributes. Tied
for fourth were Novo Nordisk and Takeda Pharmaceutical, while
Boehringer-Ingelheim and Gilead Sciences both finished fifth. Three other
sponsors—Daiichi Sankyo, Roche and Sanofi—rounded out the top 10.

According to the results, while sponsors have maintained the quality of their
relationships, they have not improved their partnerships with sites over the
past two years. As sponsors hand over an increasing amount of study conduct to
CROs and have less direct contact with sites, investigators expressed
frustration in several key areas, giving sponsors lower marks in access to
sponsor staff for problem resolution, managing study monitoring support,
prompt payment and maintaining open communication with sites.

The results also indicate that sites are frustrated with not having direct
input into running clinical trials more efficiently and improving operational
issues, from patient recruitment strategies to the use of technology at the

“Sites clearly want to voice their opinions and share insights with sponsors
and CROs on areas in which progress has been made, along with areas that may
need improvement,” said Joan Chambers, COO of CenterWatch. “Sponsors and CROs
take this feedback very seriously given its importance to successful global
clinical trial performance.”

The CenterWatch 2013 Global Investigative Site Relationship Survey was
conducted online during November/December 2012 and January 2013. Principal
investigators and study staff were asked to rate the sponsors with whom they
had worked during the past two years on a range of relationship attributes
from study planning to innovativeness. A total of 22 sponsors with sufficient
sample sizes were included in the analysis. The survey, first conducted 16
years ago, had an unprecedented response from sites this year, with 2,032
global sites responding.

Pharmaceutical and biotechnology companies interested in receiving a
comprehensive report on their company-specific results of the 2013 survey can
contact Joan Chambers at (617) 948-5100, or
Custom reports provide company-specific results compared with past survey
findings and industry benchmarks. To read the full sponsor report, subscribe
to The CenterWatch Monthly or purchase the March issue. In May, CenterWatch
will release the second part of its survey, in which global investigative
sites rate the best contract research organizations.

About CenterWatch
Since 1994, CenterWatch, has been the recognized global leader in providing
clinical trials information to a broad and influential spectrum of clinical
research professionals ranging from top sponsors and CROs to research sites
and niche providers, as well as an engaged population of patients interested
in clinical research and volunteering. For more information, visit


Cheryl Rosenfeld, Editor-in-Chief, 617-948-5100
Press spacebar to pause and continue. Press esc to stop.